Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.
BRCA2
inherited
overall survival
predictive
prognostic
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
12
11
2020
revised:
24
12
2020
accepted:
05
01
2021
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
13
1
2021
Statut:
epublish
Résumé
Our aim was to determine the prevalence, prognostic and predictive role of germline pathogenic/likely pathogenic variants (P/LPVs) in cancer predisposing genes in patients with pancreatic ductal adenocarcinoma (PDAC). Germline testing of 62 cancer susceptibility genes was performed on unselected patients diagnosed from 02/2003 to 01/2020 with PDAC, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated Centers. The main endpoints were prevalence of P/LPVs and overall survival (OS). P/LPVs in PDAC-associated and homologous recombination repair (HRR) genes were identified in 22 (4.0%) and 42 (7.7%) of 549 patients, respectively. P/LPVs were identified in 16 genes, including
Identifiants
pubmed: 33429865
pii: cancers13020198
doi: 10.3390/cancers13020198
pmc: PMC7827324
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03982446']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIPD Genetics Limited, Nicosia, Cyprus
ID : N/A
Références
Cancer Med. 2020 Jun;9(11):4004-4013
pubmed: 32255556
Cancer. 2018 Sep 1;124(17):3520-3527
pubmed: 30067863
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
JAMA. 2009 Oct 28;302(16):1790-5
pubmed: 19861671
J Clin Oncol. 2020 May 1;38(13):1442-1454
pubmed: 32073954
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074
pubmed: 29506128
JCO Precis Oncol. 2018;2:
pubmed: 31497750
Sci Rep. 2018 May 25;8(1):8105
pubmed: 29802286
Cancer. 2015 Dec 15;121(24):4382-8
pubmed: 26440929
Hered Cancer Clin Pract. 2017 Jun 28;15:9
pubmed: 28670351
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Cancer Discov. 2012 Jan;2(1):41-6
pubmed: 22585167
J Clin Oncol. 2020 Mar 1;38(7):674-685
pubmed: 31841383
J Clin Oncol. 2017 Oct 20;35(30):3382-3390
pubmed: 28767289
Genet Med. 2015 Jul;17(7):569-77
pubmed: 25356972
Br J Cancer. 2012 Dec 4;107(12):2005-9
pubmed: 23099806
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer. 2018 Apr 15;124(8):1691-1700
pubmed: 29360161
Genet Med. 2019 Jan;21(1):213-223
pubmed: 29961768
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
Br J Cancer. 2020 Feb;122(3):333-339
pubmed: 31787751
J Clin Oncol. 2015 Oct 1;33(28):3124-9
pubmed: 25940717
Clin Cancer Res. 2020 Dec 15;26(24):6505-6512
pubmed: 33028596
Int J Cancer. 2019 Aug 1;145(3):686-693
pubmed: 30672594
Clin Cancer Res. 2020 Mar 15;26(6):1385-1394
pubmed: 31871297
Genet Med. 2018 Jan;20(1):119-127
pubmed: 28726808
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):207-11
pubmed: 26483394
J Clin Oncol. 2020 May 1;38(13):1378-1388
pubmed: 31976786
Gastroenterology. 2015 Mar;148(3):556-64
pubmed: 25479140